Based on 1 publication(s) in Google Scholar
IWP-2 (GMP) is >IWP-2 (HY-13912) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWP-2 is an inhibitor of Wnt processing and secretion with an IC50 of 27 nM. IWP-2 targets the membrane-bound O-acyltransferase porcupine (Porcn) and blocks Wnt ligand palmitoylation.
For research use only. We do not sell to patients.
- CAS No.: 686770-61-6
- Formula: C22H18N4O2S3
- Molecular Weight:466.60
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) IWP-2 (GMP)
More
Biological Activity
Description
IC50 & Target
IC50: 27 nM (Wnt)[1]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CAPAN-1 | EC50 |
2.05 μM
Compound: IWP-2
|
Antiproliferative activity against human Capan1 cells after 48 hrs by MTT assay
Antiproliferative activity against human Capan1 cells after 48 hrs by MTT assay
|
[PMID: 29630366] |
| HEK293 | EC50 |
2.76 μM
Compound: IWP-2
|
Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay
Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay
|
[PMID: 29630366] |
| HT-29 | EC50 |
4.67 μM
Compound: IWP-2
|
Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
|
[PMID: 29630366] |
| MIA PaCa-2 | EC50 |
1.9 μM
Compound: IWP-2
|
Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay
Antiproliferative activity against human MIAPaCa2 cells after 48 hrs by MTT assay
|
[PMID: 29630366] |
| PANC-1 | EC50 |
2.33 μM
Compound: IWP-2
|
Antiproliferative activity against human PANC1 cells after 48 hrs by MTT assay
Antiproliferative activity against human PANC1 cells after 48 hrs by MTT assay
|
[PMID: 29630366] |
| SW-620 | EC50 |
1.9 μM
Compound: IWP-2
|
Antiproliferative activity against human SW620 cells after 48 hrs by MTT assay
Antiproliferative activity against human SW620 cells after 48 hrs by MTT assay
|
[PMID: 29630366] |
In Vitro
IWP-2 (GMP) (2?μM, in the first 4?days of Stage IV induction medium) reprograms human somatic cells to pluripotent stem cells[1].
IWP-2 (GMP) (5?μM, day 3 to 5) induces cardiac differentiation of hiPSCs[2].
IWP-2 (GMP) (5 μM, day 1 to 3) increasing the expression of cardiac progenitors and cardiac genes (MYL2, TNNI3, and TNNT2) in hiPSCs[3].
IWP-2 (GMP) (5 μM, day 5-7) together with PIP-S2 induces cardiac mesoderm differentiates into functional cardiomyocytes[4].
IWP-2 (GMP) (5 μM, treated at day 3) induces cardiomyocyte differentiation when applied following a pretreatment with Laduviglusib (GMP) (HY-10182G)[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:hiPSCs
-
Concentration:5 μM
-
Incubation Time:day 1 to 3
-
Result:Reduced the expression of anti-cardiac mesoderm genes, and increased the expression of cardiac progenitors and cardiac genes (MYL2, TNNI3, and TNNT2).
Chemical Information
-
CAS No. 686770-61-6
-
Appearance Solid
-
Molecular Weight 466.60
-
Formula C22H18N4O2S3
-
Color White to off-white
-
SMILES
O=C(NC1=NC2=CC=C(C)C=C2S1)CSC3=NC(CCS4)=C4C(N3C5=CC=CC=C5)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Nat Protoc
Standardized production of hPSC-derived cardiomyocyte aggregates in stirred spinner flasks. [Abstract]2024 Jul;19(7):1911-1939. PMID: 38548938
Solvent & Solubility
In Vitro:
DMSO : 2 mg/mL (4.29 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Guan J et al. Chemical reprogramming of human somatic cells to pluripotent stem cells. Nature. 2022;605(7909):325-331. [Content Brief]
[2]. Hamad S, et al. Generation of human induced pluripotent stem cell-derived cardiomyocytes in 2D monolayer and scalable 3D suspension bioreactor cultures with reduced batch-to-batch variations. Theranostics. 2019 Sep 25;9(24):7222-7238. [Content Brief]
[3]. Le MNT, et al. Auto/paracrine factors and early Wnt inhibition promote cardiomyocyte differentiation from human induced pluripotent stem cells at initial low cell density. Sci Rep. 2021 Nov 2;11(1):21426. [Content Brief]
[4]. Taniguchi J, et al. A synthetic DNA-binding inhibitor of SOX2 guides human induced pluripotent stem cells to differentiate into mesoderm. Nucleic Acids Res. 2017 Sep 19;45(16):9219-9228. [Content Brief]
[5]. Lian X, Zhang J, et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions. Nat Protoc. 2013 Jan;8(1):162-75. [Content Brief]
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1432 mL | 10.7158 mL | 21.4316 mL | 53.5791 mL |